Trump strikes new drug pricing deals with nine midsized drugmakers
U.S. President Donald Trump delivers remarks on his administration’s healthcare policies, in the Oval Office at the White…
FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that…
Amid the chip bear market, healthcare is breaking out: Chart of the Day
Moderna (MRNA) stock doubled on Wednesday and stole the show. But healthcare had already been quietly breaking out…
CNBC Daily Open: Watching Iran’s economy; a losing game for bonds
Treasury Secretary Scott Bessent speaking to CNBC on May 14th, 2026 from Beijing, China. CNBC Hello, this is…
Foundayo: Eli Lilly wins U.K. approval, challenging Wegovy weight-loss pill
Eli Lilly has won its first approval to sell its weight-loss drug Foundayo outside the U.S., allowing it…
Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters The diverging paths of…
We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company’s portfolio of…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
Hantavirus cases spark surge in pharma, biotech stocks — here’s why
ILLUSTRATION of hantavirus testing concept with laboratory tubes containing cotton swabs and HANTAVIRUS labels photographed in front of…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…